Rachel Abbott
Vorstandsvorsitzender bei Pan Cancer T
Aktive Positionen von Rachel Abbott
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Pan Cancer T
Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Vorstandsvorsitzender | 12.05.2023 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2023 | 12.05.2023 |
Karriereverlauf von Rachel Abbott
Ausbildung von Rachel Abbott
University of Oxford | Doctorate Degree |
Statistik
International
Niederlande | 2 |
Vereinigtes Königreich | 2 |
Operativ
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Pan Cancer T
Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Health Technology |
- Börse
- Insiders
- Rachel Abbott
- Erfahrung